Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Development > Ortataxel

OrtataxelSpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

A third generation taxane classified as a New Chemical Entity (NCE)

Target Indications

  • Solid tumors
  • Has potential to be active in tumors resistant to paclitaxel and docetaxel

Route of Administration

  • Intravenous
  • Orally bioavailable

Mode of Action

  • Microtubule stabilization leading to mitotic arrest
  • Overcomes taxane resistence based on PgP-170 overexpression

Properties

  • Safety data from Phase 1 and Phase 2 studies show a similar toxicity/tolerance profile to paclitaxel

Status

  • Phase 2 trials

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Market OpportunitiesSpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Ortatexel

Status

Phase 2 studies in taxane-refractory solid tumors have indicated a substantial level of antitumor activity

Market

The top (4) taxanes sold over $3 Billion worldwide in 2006.